Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy
Jacques Thibodeau1, Marie-Claude Bourgeois-Daigneault, Réjean Lapointe
1Laboratoire d'Immunologie Moléculaire; Département de Microbiologie et Immunologie; Université de Montréal; Montréal, QC Canada.
Abstract:
The success of immunotherapy relies on the participation of all arms of the immune system and the role of CD4+ T lymphocytes in preventing tumor growth is now well established. Understanding how tumors evade immune responses holds the key to the development of cancer immunotherapies. In this review, we discuss how MHC Class II expression varies in cancer cells and how this influences antitumor immune responses. We also discuss the means that are currently available for harnessing the MHC Class II antigen presentation pathway for the development of efficient vaccines to activate the immune system against cancer.
More Related Videos
10:04Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Related Concept Videos
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
Tumor Immunotherapy
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
